EXAM SERIES
NURS 6521 Advanced
Pharmacology —
Midterm Exam (2)
Comprehensive Exam — Questions and Answers
150 Questions
with Answers and Complete Rationales
01 NURS 6521 midterm content: pharmacokinetics, pharmacogenomics,
drug interactions, anti-infectives, cardiovascular, CNS, endocrine, and
special populations
02 Answers with explanatory rationales
03 Organized by pharmacologic principles and clinical application for
advanced practice
04 Complete questions and answers
2026 EDITION
Questions and Answers • Complete Rationales
, Learner Instructions
This custom-length multiple-choice simulation contains 150 questions organized into eight sections.
The 150-question count is a user-requested custom length and does not represent an official
Walden University exam length. This document is not affiliated with, endorsed by, or published by
Walden University and does not reproduce any official Walden University examination, its secure
item pool, or its operational delivery format.
Each question has exactly four options (A, B, C, D) and one best answer.
The correct answer and a concise rationale appear immediately beneath each question.
Section allocations are simulation allocations, not official exam section counts.
Select the single best response for each item, then review the rationale to reinforce the
underlying pharmacologic principle.
Section 1: Pharmacokinetics and Pharmacodynamics
24 questions — absorption, distribution, metabolism, excretion, first-pass effect, bioavailability, half-life, steady
state, protein binding, volume of distribution, loading dose, therapeutic index, EC50, affinity, efficacy, potency.
Q1. A patient is prescribed sublingual nitroglycerin for acute angina. What is the primary
pharmacokinetic rationale for the sublingual route of administration?
A. It increases first-pass metabolism to activate the drug.
B. It bypasses hepatic first-pass metabolism, producing rapid therapeutic effect.
C. It reduces volume of distribution and limits tissue uptake.
D. It improves protein binding and prolongs duration.
Correct Answer: B. It bypasses hepatic first-pass metabolism, producing rapid therapeutic effect.
Sublingual administration delivers nitroglycerin directly into the systemic circulation through the venous
plexus beneath the tongue, avoiding the portal circulation and hepatic first-pass metabolism that would
otherwise inactivate most of the dose. This produces onset within 1–3 minutes. The other options
misstate first-pass effects, protein binding, or volume of distribution.
Q2. A drug has a half-life of 8 hours and is given once daily. Approximately how long will it take to
reach steady-state plasma concentrations with repeated dosing?
A. 40 hours
B. 80 hours
C. 16 hours
D. 8 hours
Correct Answer: A. 40 hours
Steady state is reached in approximately 4–5 half-lives regardless of dosing frequency or dose. With a
half-life of 8 hours, 5 half-lives equal 40 hours. Eight and 16 hours represent only 1–2 half-lives; 80
hours reflects 10 half-lives, which is unnecessarily long.
,Q3. A 68-year-old patient with heart failure has marked peripheral edema and fluid retention. The
provider notes that the volume of distribution (Vd) of a highly lipophilic cardiac medication will
be altered. Which best describes the expected change?
A. Vd decreases because hepatic clearance rises.
B. Vd remains unchanged because Vd depends only on protein binding.
C. Vd decreases because total body water falls.
D. Vd increases because fluid retention expands the distribution space.
Correct Answer: D. Vd increases because fluid retention expands the distribution space.
In heart failure, fluid retention and edema expand the extracellular fluid compartment, increasing the
apparent volume of distribution for many drugs and often necessitating a loading dose to achieve
therapeutic concentrations. Vd is not solely determined by protein binding, and hepatic clearance does
not directly reduce Vd.
Q4. Warfarin is highly protein-bound (approximately 99%). If a patient also begins taking
sulfamethoxazole, which competes for protein-binding sites, what is the most likely clinical
consequence?
A. Reduced half-life due to enhanced metabolism.
B. Increased total warfarin with no change in free drug.
C. Increased free warfarin levels and elevated bleeding risk.
D. Decreased free warfarin levels and reduced anticoagulation.
Correct Answer: C. Increased free warfarin levels and elevated bleeding risk.
When two highly protein-bound drugs compete for binding sites, the displaced drug (warfarin) has a
higher free (active) fraction. Only the free drug is pharmacologically active, so even a small
displacement from 99% binding significantly raises free warfarin and increases bleeding risk. Total
levels may fall, but free active drug rises.
Q5. Which statement correctly distinguishes pharmacokinetics from pharmacodynamics?
A. Pharmacokinetics describes drug receptor affinity; pharmacodynamics describes drug excretion.
B. Pharmacokinetics describes what the body does to the drug; pharmacodynamics describes what
the drug does to the body.
C. Both terms are interchangeable and describe drug metabolism.
D. Pharmacokinetics describes what the drug does to the body; pharmacodynamics describes what
the body does to the drug.
Correct Answer: B. Pharmacokinetics describes what the body does to the drug;
pharmacodynamics describes what the drug does to the body.
Pharmacokinetics (ADME — absorption, distribution, metabolism, excretion) describes the body's
effect on the drug. Pharmacodynamics describes the drug's effect on the body, including receptor
binding, efficacy, and potency. The options that reverse or merge these definitions are incorrect.
, Q6. A drug with a narrow therapeutic index requires serum peak and trough monitoring. Which of
the following best exemplifies such a drug?
A. Lithium
B. Sertraline
C. Lisinopril
D. Acetaminophen
Correct Answer: A. Lithium
Lithium has a narrow therapeutic index (typical range 0.6–1.2 mEq/L) with toxicity emerging slightly
above the therapeutic range, requiring serum monitoring. Acetaminophen, lisinopril, and sertraline
have wider therapeutic margins and do not typically require routine serum drug-level monitoring.
Q7. A loading dose of a medication is ordered for a patient with a life-threatening arrhythmia.
Which pharmacokinetic parameter most directly justifies administering a loading dose?
A. Short half-life allowing rapid steady state.
B. High renal clearance requiring dose escalation.
C. Low protein binding requiring more drug.
D. Long half-life delaying achievement of steady state with maintenance dosing alone.
Correct Answer: D. Long half-life delaying achievement of steady state with maintenance dosing
alone.
A loading dose rapidly achieves therapeutic concentrations when a drug has a long half-life (e.g.,
digoxin, amiodarone), because reaching steady state through maintenance dosing alone would take
days to weeks. Loading dose depends on Vd and desired concentration, not directly on clearance or
protein binding.
Q8. A patient receives a drug intravenously. What is the bioavailability of this drug by this route?
A. 0%
B. 50%
C. 100%
D. 75%
Correct Answer: C. 100%
Bioavailability is the fraction of administered drug reaching systemic circulation unchanged.
Intravenous administration delivers the entire dose directly into systemic circulation, so bioavailability is
100% by definition. Oral bioavailability is typically less than 100% due to incomplete absorption and
first-pass metabolism.
NURS 6521 Advanced
Pharmacology —
Midterm Exam (2)
Comprehensive Exam — Questions and Answers
150 Questions
with Answers and Complete Rationales
01 NURS 6521 midterm content: pharmacokinetics, pharmacogenomics,
drug interactions, anti-infectives, cardiovascular, CNS, endocrine, and
special populations
02 Answers with explanatory rationales
03 Organized by pharmacologic principles and clinical application for
advanced practice
04 Complete questions and answers
2026 EDITION
Questions and Answers • Complete Rationales
, Learner Instructions
This custom-length multiple-choice simulation contains 150 questions organized into eight sections.
The 150-question count is a user-requested custom length and does not represent an official
Walden University exam length. This document is not affiliated with, endorsed by, or published by
Walden University and does not reproduce any official Walden University examination, its secure
item pool, or its operational delivery format.
Each question has exactly four options (A, B, C, D) and one best answer.
The correct answer and a concise rationale appear immediately beneath each question.
Section allocations are simulation allocations, not official exam section counts.
Select the single best response for each item, then review the rationale to reinforce the
underlying pharmacologic principle.
Section 1: Pharmacokinetics and Pharmacodynamics
24 questions — absorption, distribution, metabolism, excretion, first-pass effect, bioavailability, half-life, steady
state, protein binding, volume of distribution, loading dose, therapeutic index, EC50, affinity, efficacy, potency.
Q1. A patient is prescribed sublingual nitroglycerin for acute angina. What is the primary
pharmacokinetic rationale for the sublingual route of administration?
A. It increases first-pass metabolism to activate the drug.
B. It bypasses hepatic first-pass metabolism, producing rapid therapeutic effect.
C. It reduces volume of distribution and limits tissue uptake.
D. It improves protein binding and prolongs duration.
Correct Answer: B. It bypasses hepatic first-pass metabolism, producing rapid therapeutic effect.
Sublingual administration delivers nitroglycerin directly into the systemic circulation through the venous
plexus beneath the tongue, avoiding the portal circulation and hepatic first-pass metabolism that would
otherwise inactivate most of the dose. This produces onset within 1–3 minutes. The other options
misstate first-pass effects, protein binding, or volume of distribution.
Q2. A drug has a half-life of 8 hours and is given once daily. Approximately how long will it take to
reach steady-state plasma concentrations with repeated dosing?
A. 40 hours
B. 80 hours
C. 16 hours
D. 8 hours
Correct Answer: A. 40 hours
Steady state is reached in approximately 4–5 half-lives regardless of dosing frequency or dose. With a
half-life of 8 hours, 5 half-lives equal 40 hours. Eight and 16 hours represent only 1–2 half-lives; 80
hours reflects 10 half-lives, which is unnecessarily long.
,Q3. A 68-year-old patient with heart failure has marked peripheral edema and fluid retention. The
provider notes that the volume of distribution (Vd) of a highly lipophilic cardiac medication will
be altered. Which best describes the expected change?
A. Vd decreases because hepatic clearance rises.
B. Vd remains unchanged because Vd depends only on protein binding.
C. Vd decreases because total body water falls.
D. Vd increases because fluid retention expands the distribution space.
Correct Answer: D. Vd increases because fluid retention expands the distribution space.
In heart failure, fluid retention and edema expand the extracellular fluid compartment, increasing the
apparent volume of distribution for many drugs and often necessitating a loading dose to achieve
therapeutic concentrations. Vd is not solely determined by protein binding, and hepatic clearance does
not directly reduce Vd.
Q4. Warfarin is highly protein-bound (approximately 99%). If a patient also begins taking
sulfamethoxazole, which competes for protein-binding sites, what is the most likely clinical
consequence?
A. Reduced half-life due to enhanced metabolism.
B. Increased total warfarin with no change in free drug.
C. Increased free warfarin levels and elevated bleeding risk.
D. Decreased free warfarin levels and reduced anticoagulation.
Correct Answer: C. Increased free warfarin levels and elevated bleeding risk.
When two highly protein-bound drugs compete for binding sites, the displaced drug (warfarin) has a
higher free (active) fraction. Only the free drug is pharmacologically active, so even a small
displacement from 99% binding significantly raises free warfarin and increases bleeding risk. Total
levels may fall, but free active drug rises.
Q5. Which statement correctly distinguishes pharmacokinetics from pharmacodynamics?
A. Pharmacokinetics describes drug receptor affinity; pharmacodynamics describes drug excretion.
B. Pharmacokinetics describes what the body does to the drug; pharmacodynamics describes what
the drug does to the body.
C. Both terms are interchangeable and describe drug metabolism.
D. Pharmacokinetics describes what the drug does to the body; pharmacodynamics describes what
the body does to the drug.
Correct Answer: B. Pharmacokinetics describes what the body does to the drug;
pharmacodynamics describes what the drug does to the body.
Pharmacokinetics (ADME — absorption, distribution, metabolism, excretion) describes the body's
effect on the drug. Pharmacodynamics describes the drug's effect on the body, including receptor
binding, efficacy, and potency. The options that reverse or merge these definitions are incorrect.
, Q6. A drug with a narrow therapeutic index requires serum peak and trough monitoring. Which of
the following best exemplifies such a drug?
A. Lithium
B. Sertraline
C. Lisinopril
D. Acetaminophen
Correct Answer: A. Lithium
Lithium has a narrow therapeutic index (typical range 0.6–1.2 mEq/L) with toxicity emerging slightly
above the therapeutic range, requiring serum monitoring. Acetaminophen, lisinopril, and sertraline
have wider therapeutic margins and do not typically require routine serum drug-level monitoring.
Q7. A loading dose of a medication is ordered for a patient with a life-threatening arrhythmia.
Which pharmacokinetic parameter most directly justifies administering a loading dose?
A. Short half-life allowing rapid steady state.
B. High renal clearance requiring dose escalation.
C. Low protein binding requiring more drug.
D. Long half-life delaying achievement of steady state with maintenance dosing alone.
Correct Answer: D. Long half-life delaying achievement of steady state with maintenance dosing
alone.
A loading dose rapidly achieves therapeutic concentrations when a drug has a long half-life (e.g.,
digoxin, amiodarone), because reaching steady state through maintenance dosing alone would take
days to weeks. Loading dose depends on Vd and desired concentration, not directly on clearance or
protein binding.
Q8. A patient receives a drug intravenously. What is the bioavailability of this drug by this route?
A. 0%
B. 50%
C. 100%
D. 75%
Correct Answer: C. 100%
Bioavailability is the fraction of administered drug reaching systemic circulation unchanged.
Intravenous administration delivers the entire dose directly into systemic circulation, so bioavailability is
100% by definition. Oral bioavailability is typically less than 100% due to incomplete absorption and
first-pass metabolism.
